Use of GDNF for treating corneal defects
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 4, 2003
app pub date -
Apr 24, 2002
filing date -
Oct 29, 1999
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to the use of a glial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/or a nucleic acid containing at least a nucleotide sequence encoding the primary amino acid sequence of GDNF or the functionally active derivative or part thereof and/or of the agonist for the manufacture of a pharmaceutical composition for epidermal and stromal wound healing.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully